Glaxo Loses Court Effort to Block Generic Flonase

GlaxoSmithKline lost a bid to prevent sales of generic versions of its $900-million-a-year allergy drug Flonase.

Boehringer Ingelheim’s generic version could reach the market today after U.S. District Judge Andre Davis in Baltimore refused to block sales while Glaxo pursues a lawsuit against the Food and Drug Administration.